Neurocrine Biosciences (NASDAQ:NBIX) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.
A number of other analysts also recently issued reports on NBIX. Canaccord Genuity assumed coverage on shares of Neurocrine Biosciences in a report on Wednesday, November 21st. They set a “buy” rating and a $111.00 price target for the company. Oppenheimer set a $105.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, January 29th. Robert W. Baird decreased their price target on shares of Neurocrine Biosciences from $131.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, December 13th. Needham & Company LLC set a $104.00 price objective on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Wednesday, December 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $162.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, December 13th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $102.56.
NBIX stock opened at $84.83 on Tuesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 8.24 and a current ratio of 8.36. Neurocrine Biosciences has a 52-week low of $64.72 and a 52-week high of $126.98. The stock has a market cap of $7.96 billion, a PE ratio of 385.59, a PEG ratio of 27.34 and a beta of 1.86.
In other Neurocrine Biosciences news, insider Eiry Roberts sold 1,857 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $84.09, for a total value of $156,155.13. Following the completion of the sale, the insider now directly owns 3,143 shares in the company, valued at $264,294.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin Charles Gorman sold 7,614 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $88.16, for a total transaction of $671,250.24. Following the completion of the sale, the chief executive officer now owns 408,082 shares of the company’s stock, valued at $35,976,509.12. The disclosure for this sale can be found here. Insiders sold a total of 13,280 shares of company stock worth $1,163,054 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in Neurocrine Biosciences during the fourth quarter worth $32,000. Exane Derivatives lifted its position in Neurocrine Biosciences by 48,400.0% during the 4th quarter. Exane Derivatives now owns 485 shares of the company’s stock worth $35,000 after buying an additional 484 shares in the last quarter. Rehmann Capital Advisory Group lifted its position in Neurocrine Biosciences by 54.7% during the 3rd quarter. Rehmann Capital Advisory Group now owns 557 shares of the company’s stock worth $68,000 after buying an additional 197 shares in the last quarter. Penserra Capital Management LLC acquired a new position in Neurocrine Biosciences during the 4th quarter worth about $86,000. Finally, Arbor Wealth Management LLC bought a new stake in Neurocrine Biosciences during the 4th quarter worth about $92,000. 99.82% of the stock is currently owned by institutional investors.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Recommended Story: Day Trading – Risk Worth the Reward?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.